Glasdegib Maleate
FDA-approved product (tablet, oral), marketed as Daurismo.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute myeloid leukemia
- Cancer
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hedgehog pathway inhibitors
- FDA pharmacologic class
- Hedgehog Pathway Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli29.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Glasdegib Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ChlordiazepoxideExisting use: Alcohol dependence, Anxiety, Anxiety disorder63.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- PrazepamExisting use: Anxiety63.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- TriazolamExisting use: Insomnia63.0% AI-predicted activityagainst M. tuberculosis17 registered studies
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation62.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder62.7% AI-predicted activityagainst M. tuberculosis1 registered study
- PolythiazideExisting use: Cardiovascular disease62.7% AI-predicted activityagainst M. tuberculosis1 registered study
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease62.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more62.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- SiponimodExisting use: Multiple sclerosis62.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more62.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Fosamprenavir CalciumExisting use: HIV infection, Immunodeficiency disease, Viral disease62.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AbarelixExisting use: Neoplasm62.5% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
NCT04655391 · start 2022-06-25
Registered record
- Registry ID
- NCT04655391
- Conditions
- Recurrent Acute Myeloid Leukemia
- Interventions
- Bosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate; Glasdegib Maleate; Ivosidenib; Venetoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2022-06-25
- Completion
- 2023-12-15
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Acute Myeloid LeukemiaInterventionBosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate +3 morePhasePhase 1Registry statusWithdrawnOX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
NCT03390296 · start 2017-12-27
Registered record
- Registry ID
- NCT03390296
- Conditions
- Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
- Interventions
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600; Avelumab; Azacitidine; Gemtuzumab Ozogamicin; Glasdegib; Glasdegib Maleate; Venetoclax; Azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2017-12-27
- Completion
- 2022-02-04
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Acute Myeloid Leukemia; Refractory Acute Myeloid LeukemiaInterventionAnti-OX40 Agonist Monoclonal Antibody PF-04518600; Avelumab; Azacitidine; Gemtuzumab Ozogamicin +4 morePhasePhase 1 / Phase 2Registry statusCompleted